

The BD Hypak™ for Vaccines Glass Prefillable Syringe with 5-bevel needle

Confidently partner with BD in vaccine delivery systems

Enhance your vaccine delivery system:

- Improve needle performance by reducing needle deformation and needle hooks¹
- Reduce penetration force²
- Improve needle point resistance and reduce variability within and between batches¹




BD Hypak™ for Vaccine Glass Prefillable Syringe with 5 bevel needle

Needle point

Classic 3 bevel

cannula



- The design and cutting angles of the BD™ 5 bevel needle geometry have been engineered to provide both strength and comfort.
- This design offers better resistance, resulting in a significant reduction in axial deflection of up to 14% with the 25G 5/8in RW 5B compared to the 3B configuration¹.
- The BD™ 5 bevel needle has a larger width at the tip, in contrast to the 3 bevel needle.

BD™ 5 bevel needle vs 3 bevel needle









Improved needle penetration

Comparative bench test. BD™5 bevel needle vs 3 bevels*

Participants perceive BD[™] 5 bevel as having decreased penetration force, increased comfort, being easier to insert and overall preferable compared to BD 3 bevel needle²

Participants rated 5-bevel needles as significantly more preferable to 3-bevel needles by ~ 6 to 9 fold²

98% of home users found the 5-bevel design acceptable²

* Using 31G

No regulatory change | No stability studies required | Just a new logistic product code

Using proven technology, BD has developed the BD[™] 5 bevel needle, which offers improved resistance to axial deflection, enhancing needle tip strength and reliability¹.

*Compared to BD 3 bevel needle

- 1. BD internal study, bevel tip deflection evaluation EF 20241772, BD Medical- Pharmaceutical systems le Pont-de-Claix 23 May 2024
- 2 Geometry on Penetration Force as well as Acceptability, Preference, and Perceived Pain in Subjects with Diabetes. Hirsch L, Gibney M, Berube J, Manocchio J. Impact of a Modified Needle Tip Geometry on Penetration Force as well as Acceptability, Preference, and Perceived Pain in Subjects with Diabetes. J Diabetes Sci Technol. 2012;6(2):328-https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3380774/336

BD Medical

Pharmaceutical Systems

United States: 1 Becton Drive, Franklin Lakes, NJ 07417, +1 800 225 3310

Europe: 11 rue Aristide-Bergès, 38800 Le Pont-de-Claix, France, Phone: +33 4 76 68 36 36 - Fax: +33 4 76 68 35 05 Becton Dickinson France S.A.S - Share capital: 64 719 915 € RCS Grenoble B 056 501 711



